Compare PNRG & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | TTRX |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.2M | 281.2M |
| IPO Year | 1995 | N/A |
| Metric | PNRG | TTRX |
|---|---|---|
| Price | $195.41 | $9.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $160.00 | $8.00 |
| AVG Volume (30 Days) | 53.3K | ★ 82.5K |
| Earning Date | 04-16-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.18 | N/A |
| P/E Ratio | $101.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.40 | $2.57 |
| 52 Week High | $278.90 | $11.69 |
| Indicator | PNRG | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 58.40 |
| Support Level | $163.44 | $2.95 |
| Resistance Level | $199.67 | $10.48 |
| Average True Range (ATR) | 7.73 | 0.84 |
| MACD | 0.92 | 0.04 |
| Stochastic Oscillator | 90.58 | 72.55 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.